Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

Abstract

BackgroundWhole brain radiation therapy (WBRT), surgical resection, stereotactic radiosurgery (SRS), and combinations of the three modalities are used in the management of patients with metastatic brain tumors. We present the previously unreported survival outcomes of 275 patients treated for newly diagnosed brain metastases at Cancer Care Northwest and Gamma Knife of Spokane between 1998 and 2008.MethodsThe effects treatment regimen, age, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), primary tumor histology, number of brain metastases, and total volume of brain metastases have on patient overall survival were analyzed. Statistical analysis was performed using Kaplan-Meier survival curves, Andersen 95% confidence intervals, approximate confidence intervals for log hazard-ratios, and multivariate Cox proportional hazard models.ResultsThe median clinical follow up time was 7.2 months. On multivariate analysis, survival statistically favored patients treated with SRS alone when compared to patients treated with WBRT alone (p < 0.001), patients treated with resection with SRS when compared to patients treated with SRS alone (p = 0.020), patients in ECOG-PS class 0 when compared to patients in ECOG-PS classes 2 (p = 0.04), 3 (p < 0.001), and 4 (p < 0.001), patients in the non-small-cell lung cancer group when compared to patients in the combined melanoma and renal-cell carcinoma group (p < 0.001), and patients with breast cancer when compared to patients with non-small-cell lung cancer (p < 0.001).ConclusionsIn our analysis, patients benefited from a combined modality treatment approach and physicians must consider patient age, performance status, and primary tumor histology when recommending specific treatments regimens.

Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis

“…Retrospectively, SRS treatment relative to WBRT was associated with a higher risk of LMD occurrence as per Hsieh et al [18] (HR:2.44; 95%-CI:1.15–5.18) and Patel et al [24] (HR:5.67; 95%-CI: 1.50–21.51).…”

“…In their 2011 institutional study, Elaimy et al retrospectively compared six different treatment regimens in patients with metastatic lesions in the brain [24]. Using SRS only as a reference, they found that 15 selected patients treated with SRS following resection had a 68% lower risk of death as compared to 65 patients treated with SRS alone ( p  = 0.02).…”

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

“…Current therapeutic options include neurosurgery, radiosurgery, whole‐brain radiation, and chemotherapy. Patients treated with neuro‐ or radiosurgery appear to have a longer median survival of about 9 months . Chemotherapeutic agents such as temozolomide that are used for treating primary brain tumors are not effective for cerebral melanoma metastases .…”

Single Solitary Fibrous Tumor Brain Metastasis in a Patient with Simultaneous Adenocarcinoma of the Lung: Case Report and Review of the Literature

“…ough the literature is inconclusive about the most effective use, radiotherapy is a good adjuvant treatment before or after surgery in more complex conditions, such as in the case of an incomplete resection or if the tumor is inoperable. We have previously published clinical outcomes after radiosurgery or whole brain radiation for brain metastasis of various histologic types [19,20]. Radiation therapy is especially utilized in cases with malignant SFT, narrow margins, tumor size greater than 10 cm, and fast-growing tumors [2].…”